147 related articles for article (PubMed ID: 37597724)
1. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
Kenet G; Young G; Chuansumrit A; Matsushita T; Yadav V; Zak M; Male C
J Thromb Haemost; 2023 Nov; 21(11):3109-3116. PubMed ID: 37597724
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
Giangrande P; Abdul Karim F; Nemes L; You CW; Landorph A; Geybels MS; Curry N
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
[TBL] [Abstract][Full Text] [Related]
8. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
10. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
12. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response.
Chowdary P; Hampton K; Jiménez-Yuste V; Young G; Benchikh El Fegoun S; Cooper A; Scalfaro E; Tiede A
Thromb Haemost; 2022 Jun; 122(6):913-925. PubMed ID: 34865209
[TBL] [Abstract][Full Text] [Related]
13. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A.
Matsushita T; Mangles S
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):26-33. PubMed ID: 32558236
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
16. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A.
Tiede A; Hampton K; Jiménez-Yuste V; Young G; Benchikh El Fegoun S; Chowdary P
Haemophilia; 2022 Jan; 28(1):27-35. PubMed ID: 34562332
[TBL] [Abstract][Full Text] [Related]
17. Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
Vashi P; Batt K; Klamroth R; Mancuso ME; Majewska R; Tiede A; Mantovani LG
J Blood Med; 2021; 12():935-943. PubMed ID: 34754257
[TBL] [Abstract][Full Text] [Related]
18. Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.
Oldenburg J; Benson G; Chowdary P; Halimeh S; Matsushita T; Nørland A; Wahid MN; Nemes L
Haemophilia; 2023 Nov; 29(6):1475-1482. PubMed ID: 37729439
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
